Clinical Trial Update: YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates YTS104 cell injections for relapsed or refractory multiple myeloma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• YTS104

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING